Alliance Global Partners upgraded Obalon Therapeutics (NASDAQ:OBLN) to “buy” and raised its price target to $6.15 from 75 cents, reflecting a new valuation of ReShape Lifesciences, Obalon’s merger partner. Shares of...
Alliance Global Partners downgraded Obalon Therapeutics (NASDAQ:OBLN) to “neutral” from “buy” and slashed its price target to 90 cents from $6.40 after the company moved to explore potential financial and strategic...
The board of Obalon Therapeutics (NASDAQ:OBLN) decided to explore potential financial and strategic alternatives intended to enhance stockholder value and has retained Canaccord Genuity as its financial advisor. The...
Obalon Therapeutics (NASDAQ:OBLN) opened its second company-managed retail center in Orange County, Calif. to treat obesity with its swallowable, gas-filled intragastric balloon system. In a statement, Bill Plovanic...
BTIG lowered its price target for Obalon Therapeutics (NASDAQ:OBLN) to $7 from $13 after the company reported in-line fourth quarter results and guidance for 2018. The stock finished at $4.01 on March 5. Obalon is...